Summary
This single-arm phase 2 trial, published in The Lancet in 2016, assessed atezolizumab as a checkpoint inhibitor therapy for patients with locally advanced or metastatic urothelial carcinoma resistant to platinum-based chemotherapy. The study represents an evaluation of immunotherapeutic approaches in a difficult-to-treat cancer population where conventional chemotherapy had failed. The trial's findings contributed to the evidence base for PD-L1-targeted immunotherapy in platinum-refractory urothelial malignancy.
UK applicability
As an early-phase immunotherapy trial, the results would be relevant to UK oncology practice and NHS treatment protocols for urothelial carcinoma, particularly in establishing atezolizumab's role in the treatment algorithm for chemotherapy-refractory disease. UK cancer centres would have evaluated these findings for integration into standard care pathways.
Key measures
Objective response rate, duration of response, overall survival, adverse events, and safety profile in platinum-refractory urothelial carcinoma patients
Outcomes reported
The study evaluated the efficacy and safety of atezolizumab, a programmed death ligand-1 (PD-L1) inhibitor, in patients with locally advanced or metastatic urothelial carcinoma who had progressed after platinum-based chemotherapy treatment.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.